Gut microbiome dysbiosis in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis

• Published in: PloS one 2023-05, Vol.18 (5), p.e0285346-e0285346
• Main Authors: Jemimah, Sherlyn, Chabib, Chahd Maher Musthafa, Hadjileontiadis, Leontios, AlShehhi, Aamna
• Format: Article
• Language: English
• Subjects: Advertising executives; Aged; Alzheimer Disease; Alzheimer's disease; Alzheimers disease; Analysis; Bacteroides; Bioinformatics; Biological diversity; Biology and Life Sciences; Cognition & reasoning; Cognition disorders; Cognitive ability; Cognitive Dysfunction; Complications and side effects; Diagnosis; Digestive system; Discriminant analysis; Dysbacteriosis; Dysbiosis; Ecology and Environmental Sciences; Female; Gastrointestinal Microbiome; Health aspects; Heterogeneity; Humans; Impairment; Intestinal microflora; Male; Medical research; Medicine and Health Sciences; Medicine, Experimental; Meta-analysis; Microbiomes; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Middle Aged; Neurodegeneration; Neurodegenerative diseases; Ordination; Perturbation; Phascolarctobacterium; Physical Sciences; Prodromal Symptoms; Relative abundance; Research and Analysis Methods; Species richness; Subgroups; Systematic review; Variance analysis; Vocabularies & taxonomies
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0285346

Alzheimer's disease (AD) is a neurodegenerative disorder that causes gradual memory loss. AD and its prodromal stage of mild cognitive impairment (MCI) are marked by significant gut microbiome perturbations, also known as gut dysbiosis. However, the direction and extent of gut dysbiosis have not been elucidated. Therefore, we performed a meta-analysis and systematic review of 16S gut microbiome studies to gain insights into gut dysbiosis in AD and MCI. We searched MEDLINE, Scopus, EMBASE, EBSCO, and Cochrane for AD gut microbiome studies published between Jan 1, 2010 and Mar 31, 2022. This study has two outcomes: primary and secondary. The primary outcomes explored the changes in α-diversity and relative abundance of microbial taxa, which were analyzed using a variance-weighted random-effects model. The secondary outcomes focused on qualitatively summarized β-diversity ordination and linear discriminant analysis effect sizes. The risk of bias was assessed using a methodology appropriate for the included case-control studies. The geographic cohorts' heterogeneity was examined using subgroup meta-analyses if sufficient studies reported the outcome. The study protocol has been registered with PROSPERO (CRD42022328141). Seventeen studies with 679 AD and MCI patients and 632 controls were identified and analyzed. The cohort is 61.9% female with a mean age of 71.3±6.9 years. The meta-analysis shows an overall decrease in species richness in the AD gut microbiome. However, the phylum Bacteroides is consistently higher in US cohorts (standardised mean difference [SMD] 0.75, 95% confidence interval [CI] 0.37 to 1.13, p < 0.01) and lower in Chinese cohorts (SMD -0.79, 95% CI -1.32 to -0.25, p < 0.01). Moreover, the Phascolarctobacterium genus is shown to increase significantly, but only during the MCI stage. Notwithstanding possible confounding from polypharmacy, our findings show the relevance of diet and lifestyle in AD pathophysiology. Our study presents evidence for region-specific changes in abundance of Bacteroides, a major constituent of the microbiome. Moreover, the increase in Phascolarctobacterium and the decrease in Bacteroides in MCI subjects shows that gut microbiome dysbiosis is initiated in the prodromal stage. Therefore, studies of the gut microbiome can facilitate early diagnosis and intervention in Alzheimer's disease and perhaps other neurodegenerative disorders.